The Filing Desk

Amarin

AMRN · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

AMRN · Last close · November 19, 2026
$11.26
Value Amarin yourself

Amarin's revenue fell 6.5% to $214 million in fiscal 2025. Its operating margin was −23.5%, up from −40.1% a year earlier. The diluted share count rose 1.0%.

AMARIN CORP PLC\UK Latest fiscal year ended December 31, 2025 10-K filed March 2, 2026 · 0001193125-26-085818 Updated
Revenue
$214M
6.5%
Operating margin
−23.5%
16.7 pts
Net income
−$39M
 
Free cash flow
—
 
Return on equity
−8.2%
7.6 pts
Market cap
$4.8B
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Amarin does

Amarin is a pharmaceutical company that sells one product, VASCEPA (icosapent ethyl), a prescription medicine used to lower triglyceride levels and to reduce heart and blood vessel risk in certain high-risk patients who already take statins. In Europe the product is sold under the name VAZKEPA. Customers in the United States are mainly large drug wholesalers, which resell it to pharmacies.

Amarin reports one business segment. It sells VASCEPA itself in the United States and relies on licensing partners in other regions, and it supplies the drug to those partners. In June 2025 it signed a long-term license and supply agreement with Recordati, which now takes over selling VAZKEPA in Europe. In the United States, Amarin competes with generic versions of the drug, several of which have been on the market since a court ruling went against it in 2020.

Amarin is incorporated in England and Wales, has its principal office in Dublin, Ireland, and keeps its main US office in New Jersey. It cut staff as part of the Recordati deal.

Its biggest risks, as it describes them

  • Depending almost entirely on one product, VASCEPA, in the United States and abroad.
  • Generic versions of the drug competing in the United States and cutting into its revenue.
  • Partners and drug-pricing approvals in other countries may not bring the sales it hopes for.
  • New data or readings of its clinical trial results could change how the drug is seen.
  • Regulators closely watch how the drug is made, supplied and promoted.
From Amarin's annual report on Form 10-K, filed March 2, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Amarin lost money in fiscal 2025: a net loss of $39 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments454309321294303
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage81.4x−7,057.9x−8,448.5x−13,113.9x−7,167.1x
Current ratio2.4x2.7x2.8x3.3x3.3x
Quick ratio1.7x1.8x1.8x2.4x2.3x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Amarin's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Amarin reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40———
Altman Z''−1.02−2.30−2.07
Accruals ratio−7.7%−6.8%−6.7%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positivePassFailPass
Return on assets rosePassFailPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assets———
Current ratio rosePassPassPass
Share count didn't riseFailFailFail
Gross margin roseFailFailPass
Revenue rose relative to assetsPassFailPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Amarin side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
AmarinFY25−6.5%−23.5%————
Vanda PharmaceuticalsFY258.7%−70.0%−51.1%———Compare
IDEAYA BiosciencesFY253,024.4%−72.8%−33.6%———Compare
Puma BiotechnologyFY25−0.9%16.3%18.3%48.2%−1.4x8Compare
Akebia TherapeuticsFY2547.5%9.9%28.7%—−5.5x7Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue130181229430614583369307229214
Revenue growth59.1%39.2%26.6%87.5%42.9%−5.0%−36.7%−16.9%−25.5%−6.5%
Gross profit9613617533448346224216681121
Research and development50475634392930222120
Operating income−66−46−108−24−2010−106−68−92−50
Net income−86−68−116−23−188−106−59−82−39
Diluted EPS (US$)−0.41−0.25−0.39−0.07−0.050.02−0.26−0.15−0.20−0.09
Diluted shares (millions)212271297342382402401408411415
Cash flow
Cash from operations−72−33−95−9−22−66−1807−317
Capital expenditure00020—————
Free cash flow−72−33−95−12−22—————
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation14141931463726161814
Balance sheet at fiscal year end
Cash and short-term investments9874249645501454309321294303
Debt incl. finance leases94928050——————
Total assets1671623868829661,068886832685671
Total liabilities176227233274338401291280199212
Shareholders' equity−9−65152608628667595552486459
Margins and ratios
Gross margin73.6%75.2%76.2%77.7%78.6%79.2%65.7%53.9%35.6%56.6%
Operating margin−50.5%−25.1%−47.2%−5.7%−3.2%1.8%−28.7%−22.0%−40.1%−23.5%
Net margin−66.4%−37.5%−50.8%−5.3%−2.9%1.3%−28.7%−19.3%−36.0%−18.2%
Free cash flow margin−55.2%−18.1%−41.3%−2.8%−3.6%—————
Rule of 40 (growth + FCF margin)3.9%21.1%−14.8%84.7%39.3%—————
Return on capital——————————
Return on equity——−267.0%−6.0%−2.9%1.2%−16.8%−10.3%−15.8%−8.2%
Return on assets−50.8%−41.3%−42.5%−3.6%−1.9%0.8%−10.8%−6.9%−10.8%−5.7%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Amarin's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Amarin.